Tvardi Therapeutics
TVRD
121 hedge funds and large institutions have $222M invested in Tvardi Therapeutics in 2018 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 30 increasing their positions, 35 reducing their positions, and 20 closing their positions.
5% more capital invested
Capital invested by funds: $211M → $222M (+$10.8M)
0.06% more ownership
Funds ownership: 1.47% → 1.52% (+0.06%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 127 → 121 (-6)
14% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 35
25% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 20
46% less call options, than puts
Call options by funds: $3.9M | Put options by funds: $7.22M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$8.66M |
| 2 |
NC
Nexthera Capital
New York
|
+$4.73M |
| 3 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$2.84M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.88M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.48M |
| 2 |
Morgan Stanley
New York
|
-$1.96M |
| 3 |
Millennium Management
New York
|
-$1.37M |
| 4 |
Squarepoint
New York
|
-$1.08M |
| 5 |
Goldman Sachs
New York
|
-$656K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RJA
126
Raymond James & Associates
St Petersburg,
Florida
| – | -$199K | -453 | Closed |
|
127
Two Sigma Advisers
New York
| – | -$198K | -450 | Closed |
|
|
ARTA
128
A.R.T. Advisors
New York
| – | -$197K | -447 | Closed |
|
|
PP
129
Paloma Partners
Greenwich,
Connecticut
| – | -$167K | -378 | Closed |
|
|
FRM
130
Fox Run Management
Greenwich,
Connecticut
| – | -$157K | -356 | Closed |
|
131
Simplex Trading
Chicago,
Illinois
| – | -$171K | -352 | Closed |
|
|
CAN
132
Cetera Advisor Networks
El Segundo,
California
| – | -$125K | -293 | Closed |
|
133
D.E. Shaw & Co
New York
| – | -$127K | -287 | Closed |
|
|
MA
134
MANA Advisors
New York
| – | -$125K | -283 | Closed |
|
135
Russell Investments Group
London,
United Kingdom
| – | -$80K | -173 | Closed |
|
136
Pacer Advisors
Malvern,
Pennsylvania
| – | -$54K | -122 | Closed |
|
137
Parallax Volatility Advisers
San Francisco,
California
| – | -$50K | -113 | Closed |
|
|
BBHC
138
Brown Brothers Harriman & Co
New York
| – | -$38K | -86 | Closed |
|
|
ML
139
McAdam LLC
Philadelphia,
Pennsylvania
| – | +$485 | +1 | New |
|
TVRD Hedge Fund Activity: Q1 2018 in Review
121 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q1 2018, worth a combined $222M — up 5.1% from $211M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of TVRD and 15 opened new positions — a net loss of 5 holders — while 35 trimmed existing stakes and 30 added.
The largest buyer was State Street, adding an estimated $8.66M. The largest seller was Fidelity Investments, cutting an estimated $2.48M.
- 121 institutional investors held Tvardi Therapeutics (TVRD) as of Q1 2018, down from 127 in Q4 2017.
- Funds reported $222M of Tvardi Therapeutics stock for Q1 2018, up 5.1% quarter-over-quarter.
- 15 funds opened new Tvardi Therapeutics positions in Q1 2018 and 20 closed out, a net change of -5 holders.
- The largest Tvardi Therapeutics buyer in Q1 2018 was State Street, an estimated $8.66M added.
- The largest Tvardi Therapeutics seller in Q1 2018 was Fidelity Investments, an estimated $2.48M sold.
Based on aggregated 13F filings for Q1 2018.